

PEDIATRIC SURGERY Update Vol. 50 No. 02 FEBRUARY 2018

Gardner Fibroma

Gardner fibromas are superficial, poorly circumscribed benign soft tissue tumors and sometimes painful lesions which consist mainly of thick haphazardly arranged collagen bundles with few interspersed spindle cells of fibroblast type. Males and females are equally affected. They are associated with Gardner syndrome and may be the first manifestation of the disease. Gardner fibromas are precursors lesion of desmoid tumors. Both Gardner fibromas and desmoid tumors are associated with Gardner syndrome. Gardner syndrome is an autosomal dominant inherited disease characterized by the triad of gastrointestinal adenomatous polyps, multiple osteomas and mesenchymal tumors of the skin and soft tissue. Gardner syndrome and Familial adenomatous polyposis (FAP) are considered to be variants of the same disease. Both are caused by mutation in the APC gene located on chromosome 5g21. The cutaneous and bone abnormalities precede development of polyposis with approximately 10 years. Other cutaneous manifestations of Gardner syndrome include neurofibromas, lipomas, leiomyomas and pigmented skin lesions. The diagnosis of Gardner syndrome can be made by genetic testing or by colonoscopy showing multiple polyps. The most common sites affected by Gardner fibromas include the back, paraspinal region and chest wall though they may appear in any part of the body. Gardner fibromas are most commonly observed in the first decade of life. The management of a Gardner fibroma consists of wide total local excision something that can be technically demanding or even impossible because of the poor circumscription or anatomic boundaries this type of tumor is characterized. Prediction of Gardner fibroma behavior is impossible, but in general 5-10% resolve spontaneously, 30% undergo cycles of progression and resolution and 50% remain stable after diagnosis, but 10% progress rapidly growing to massive sizes and infiltrating adjacent tissue. The development of a Gardner fibroma raise sentinel suspicion of Gardner syndrome or FAP which should be diagnosed by endoscopy or genetic testing.

References:

1- Coffin CM, Hornick JL, Zhou H, Fletcher CD: Gardner fibroma: a clinicopathologic and immunohistochemical analysis of 45 patients with 57 fibromas. Am J Surg Pathol. 31(3):410-6, 2007

2- Levesque S, Ahmed N, Nguyen VH, Nahal A, Blumenkrantz M, Puligandla P, Chong G, Foulkes WD: Neonatal Gardner fibroma: a sentinel presentation of severe familial adenomatous polyposis. Pediatrics. 126(6):e1599-602, 2010

3- van Geel MJ, Wijnen M, Hoppenreijs EP, Gierenz N, Spruijt L, van Koolwijk MP, Flucke U, Blokx WA, Seyger MM: Hypertrophic left calf and multiple flesh-coloured subcutaneous tumours in a 5-year-old girl: a quiz. Gardner-associated fibroma. Acta Derm Venereol. 94(5):619-22, 2014

4- Vieira J, Pinto C, Afonso M, do Bom Sucesso M, Lopes P, Pinheiro M, Veiga I, Henrique R, Teixeira MR: Identification of previously unrecognized FAP in children with Gardner fibroma. Eur J Hum Genet.

23(5):715-8, 2015

5- Schafer M, Kadmon M, Schmidt W, Treiber I, Moog U, Sutter C, Stehr M: Neonatal Gardner Fibroma Leads to Detection of Familial Adenomatous Polyposis: Two Case Reports. European J Pediatr Surg Rep. 4(1):17-21, 2016

6- Santoro C, Giugliano T, Bifano D, D'Anna C, D'Onofrio V, Perrotta S: From Gardner fibroma diagnosis to constitutional APC mutation detection: a one-way street. Clin Case Rep. 5(10):1557-1560, 2017

Renal Rhabdoid Tumor

Renal rhabdoid tumors (RRT) are highly malignant neoplasms first described in the kidney of young children. Rhabdoid tumors also arise in extra-renal sites such as soft tissue and central nervous system. RRT have a common genetic abnormality, namely the mutation or deletion of the SMARCB1/hSNF5/INI-1 gene located at chromosome 22q11.2. A concomitant brain tumor is present in almost 21% of children with a RRT. The exact cell type of derivation of Rhabdoid tumors of the kidney remains unknown though a possible origin has been ascribed to primitive cells located in then renal medulla. Histologically RRT cells are arranged as diffuse sheets or as alveolar or trabecular pattern. RRT can occur sporadically or as part of hereditary cancer syndrome known as Rhabdoid Tumor Predisposition Syndrome. Prognosis of malignant rhabdoid tumor of the kidney is related to age at time of diagnosis and stage of disease and not to the location of the tumor. The younger the child with RRT the less probable is his long-term survival. Older than age 1.5 years at diagnosis regardless of anatomic location has higher overall survival. RRT is commonly diagnosed between 0-3 years of age with a peak incidence between age of 10-18 months. It is also associated with extensive metastasis at time of diagnosis and as mentioned before can have synchronous brain tumor. There is no standard management for RRT and the prognosis is very poor with overall survival of 15-36% though more recent treatment regimens using surgery, radiotherapy, high dose chemotherapy and autologous stem cell rescue may increase survival to 66.7% with a median follow up of almost two years. Surgical treatment of RRT follows that used in Wilms tumor. Biopsy of the primary tumor is usually not carried out prior to removal to avoid rupture of the tumor capsule and spillage of tumor cells. Germline analysis is recommended for individuals of all ages with rhabdoid tumors and prenatal diagnosis can be performed in families with a known SMARCB1 alteration. Surveillance guidelines for patients with germline mutation have been developed.

References:

1- Gadd S, Sredni ST, Huang CC, Perlman EJ; Renal Tumor Committee of the Children's Oncology Group: Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Lab Invest. 90(5):724-38, 2010

2- van den Heuvel-Eibrink MM, van Tinteren H, Rehorst H, Coulombe A, Patte C, de Camargo B, de Kraker J, Leuschner I, Lugtenberg R, Pritchard-Jones K, Sandstedt B, Spreafico F, Graf N, Vujanic GM: Malignant rhabdoid tumors of the kidney (MRTKs), registered on recent SIOP protocols from 1993 to 2005: a report of the SIOP renal tumour study group. Pediatr Blood Cancer 56(5):733-7, 2011

3- Shukla D, Pradhan A, Bhardwaj M, Malhotra V: Malignant rhabdoid tumor of kidney and brain in an infant. Indian Pediatr. 52(1):65-6, 2015

4- Lee JS, Sanchez TR, Wootton-Gorges S: Malignant renal tumors in children. J Kidney Cancer VHL. 2(3):84-89, 2015

5- Brok J, Treger TD, Gooskens SL, van den Heuvel-Eibrink MM, Pritchard-Jones K: Biology and treatment of renal tumours in childhood. Eur J Cancer. 68:179-195, 2016

6- Farber BA, Shukla N, Lim IIP, Murohy JM, La Quaglia MP: Prognostic factors and survival in non-central nervous system rhabdoid tumors. J Pediatr Surg 52: 373-376, 2017

Endocarditis Prophylaxis

Infective endocarditis is a rare potentially life threatening infection of the heart valve or endocardium. Congenital heart disease (CHD) and palliative or corrective surgery associated to the structural defect are the two most common predisposing conditions for the development of infective endocarditis. Cyanotic CHD, left-sided lesions and endocardial cushion defects are associated with increase risk of infective endocarditis in children. The risk of developing infective endocarditis is substantially elevated during the six months postoperative period of cardiac surgery and in children less than three years of age. Lesions associated with cyanosis at birth (dextrotransposition of great arteries and tetralogy of Fallot) has the highest incidence of infective endocarditis. Infective endocarditis is less common in right sided than left sided lesion. Endothelialization of prosthetic material introduced by cardiac surgery occurs within six months following the procedure. The most common organism covered during endocarditis prophylaxis is Streptococcus viridans a commensal bacteria that populate the skin, oral, gastrointestinal and respiratory mucosa. The American Heart Association guidelines recommend providing prophylactic antibiotic coverage for endocarditis to children who are to undergo a procedure including dental which has an unrepaired cyanotic CHD including palliative shunts and conduits, completely repaired CHD with prosthetic material or device (whether placed by surgery or catheter intervention) during the first six months after the procedure. Also prophylaxis is recommended for repaired CHD with residual defect at the site or adjacent to the site of a prosthetic patch or prosthetic device (which inhibit endothelialization) and cardiac transplantation recipients who develop cardiac valvulopathy. Any child with CHD undergoing a general surgery or dental procedure should be evaluated by its pediatric cardiologist in seek of advice regarding endocarditis prophylaxis. Procedures that require prophylaxis include dental including manipulation of gingival tissue or perforation of oral mucosa, tonsillectomy and adenoidectomy. Endocarditis prophylaxis is no longer needed for gastrointestinal and genitourinary procedures since they all receive broad spectrum prophylaxis by nature of the clean contaminated classification.

References:

1- Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ: Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors. Circulation. 128(13):1412-9, 2013

2- Al-Fouzan AF, Al-Shinaiber RM, Al-Baijan RS, Al-Balawi MM: Antibiotic prophylaxis against infective endocarditis in adult and child patients. Knowledge among dentists in Saudi Arabia. Saudi Med J. 36(5):554-61, 2015

3- Grattan MJ, Power A, Fruitman DS, Islam S, Mackie AS: The Impact of Infective Endocarditis Prophylaxis Recommendations on the Practices of Pediatric and Adult Congenital Cardiologists. Can J Cardiol. 31(12):1497.e23-8, 2015

4- Thornhill MH, Dayer M, Lockhart PB, McGurk M, Shanson D, Prendergast B, Chambers JB: Guidelines on prophylaxis to prevent infective endocarditis. Br Dent J. 220(2):51-6, 2016

5- Isaacs D: Antibiotic prophylaxis for infective endocarditis: A systematic review and meta-analysis. J

Paediatr Child Health. 53(9):921-922, 2017

*Edited by: Humberto Lugo-Vicente, MD, FACS, FAAP Professor of Pediatric Surgery, University of Puerto Rico - School of Medicine, Rio Piedras, Puerto Rico. Director - Pediatric Surgery, San Jorge Childrens Hospital. Address: P.O. Box 10426, Caparra Heights Station, San Juan, Puerto Rico USA 00922-0426. Tel (787)-999-9450 E-mail: *titolugo@coqui.net* Internet: http://home.coqui.net/titolugo

ISSN 1089-7739